BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33457075)

  • 1. Anti-NKG2D single domain-based antibodies for the modulation of anti-tumor immune response.
    Raynaud A; Desrumeaux K; Vidard L; Termine E; Baty D; Chames P; Vigne E; Kerfelec B
    Oncoimmunology; 2020 Dec; 10(1):1854529. PubMed ID: 33457075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity.
    Zhang C; Röder J; Scherer A; Bodden M; Pfeifer Serrahima J; Bhatti A; Waldmann A; Müller N; Oberoi P; Wels WS
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The NKG2D/NKG2DL Axis in the Crosstalk Between Lymphoid and Myeloid Cells in Health and Disease.
    Stojanovic A; Correia MP; Cerwenka A
    Front Immunol; 2018; 9():827. PubMed ID: 29740438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leveraging NKG2D Ligands in Immuno-Oncology.
    Fuertes MB; Domaica CI; Zwirner NW
    Front Immunol; 2021; 12():713158. PubMed ID: 34394116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural killer group 2D receptor and its ligands in cancer immune escape.
    Duan S; Guo W; Xu Z; He Y; Liang C; Mo Y; Wang Y; Xiong F; Guo C; Li Y; Li X; Li G; Zeng Z; Xiong W; Wang F
    Mol Cancer; 2019 Feb; 18(1):29. PubMed ID: 30813924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arming cytotoxic lymphocytes for cancer immunotherapy by means of the NKG2D/NKG2D-ligand system.
    Lazarova M; Wels WS; Steinle A
    Expert Opin Biol Ther; 2020 Dec; 20(12):1491-1501. PubMed ID: 32726145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Targeting of Glioblastoma Cells with Bispecific Killer Cell Engagers Directed to EGFR and ErbB2 (HER2) Facilitates Effective Elimination by NKG2D-CAR-Engineered NK Cells.
    Kiefer A; Prüfer M; Röder J; Pfeifer Serrahima J; Bodden M; Kühnel I; Oberoi P; Wels WS
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
    Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
    Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting NKG2D/NKG2DL axis in multiple myeloma therapy.
    Liu Z; Wang H; Liu H; Ding K; Shen H; Zhao X; Fu R
    Cytokine Growth Factor Rev; 2024 Apr; 76():1-11. PubMed ID: 38378397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific NKG2D-CD3 and NKG2D-CD16 fusion proteins for induction of NK and T cell reactivity against acute myeloid leukemia.
    Märklin M; Hagelstein I; Koerner SP; Rothfelder K; Pfluegler MS; Schumacher A; Grosse-Hovest L; Jung G; Salih HR
    J Immunother Cancer; 2019 May; 7(1):143. PubMed ID: 31142382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heat-killed Helicobacter pylori upregulates NKG2D ligands expression on gastric adenocarcinoma cells via Toll-like receptor 4.
    Hernández C; Toledo-Stuardo K; García-González P; Garrido-Tapia M; Kramm K; Rodríguez-Siza JA; Hermoso M; Ribeiro CH; Molina MC
    Helicobacter; 2021 Aug; 26(4):e12812. PubMed ID: 33928707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The NKG2D axis: an emerging target in cancer immunotherapy.
    Lazarova M; Steinle A
    Expert Opin Ther Targets; 2019 Apr; 23(4):281-294. PubMed ID: 30732494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status.
    Raab S; Steinbacher J; Schmiedel BJ; Kousis PC; Steinle A; Jung G; Grosse-Hovest L; Salih HR
    J Immunol; 2014 Oct; 193(8):4261-72. PubMed ID: 25217158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting NKG2DL with Bispecific NKG2D-CD16 and NKG2D-CD3 Fusion Proteins on Triple-Negative Breast Cancer.
    Kaidun P; Holzmayer SJ; Greiner SM; Seller A; Tegeler CM; Hagelstein I; Mauermann J; Engler T; Koch A; Hartkopf AD; Salih HR; Märklin M
    Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
    Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation, affinity maturation, and characterization of a human anti-human NKG2D monoclonal antibody with dual antagonistic and agonistic activity.
    Kwong KY; Baskar S; Zhang H; Mackall CL; Rader C
    J Mol Biol; 2008 Dec; 384(5):1143-56. PubMed ID: 18809410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
    Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
    Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human IgG1 antibodies antagonizing activating receptor NKG2D on natural killer cells.
    Steigerwald J; Raum T; Pflanz S; Cierpka R; Mangold S; Rau D; Hoffmann P; Kvesic M; Zube C; Linnerbauer S; Lumsden J; Sriskandarajah M; Kufer P; Baeuerle PA; Volkland J
    MAbs; 2009; 1(2):115-27. PubMed ID: 20061825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MICA immune complex formed with alpha 3 domain-specific antibody activates human NK cells in a Fc-dependent manner.
    Du C; Bevers J; Cook R; Lombana TN; Rajasekaran K; Matsumoto M; Spiess C; Kim JM; Ye Z
    J Immunother Cancer; 2019 Aug; 7(1):207. PubMed ID: 31387641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.